Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.

Dasa, Siva Sai Krishna; Diakova, Galina; Suzuki, Ryo; Mills, Anne M; Gutknecht, Michael F; Klibanov, Alexander L; Slack-Davis, Jill K; Kelly, Kimberly A

Dasa, Siva Sai Krishna; Diakova, Galina; Suzuki, Ryo; Mills, Anne M; Gutknecht, Michael F; Klibanov, Alexander L; Slack-Davis, Jill K; Kelly, Kimberly A.

Affiliation

Dasa SSK; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Diakova G; Cancer center, University of Virginia, Charlottesville, VA, USA.
Suzuki R; Cancer center, University of Virginia, Charlottesville, VA, USA.
Mills AM; Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA.
Gutknecht MF; Division of Cardiovascular Medicine, University of Virginia, Charlottesville, VA, USA.
Klibanov AL; Department of Pathology, University of Virginia, Charlottesville, VA, USA.
Slack-Davis JK; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
Kelly KA; Cancer center, University of Virginia, Charlottesville, VA, USA.

Theranostics ; 8(10): 2782-2798, 2018.

Article de En | MEDLINE | ID: mdl-29774075

Sujet(s)
Mots clés

epithelial ovarian cancer; genomics; pharmacodynamics; pharmacokinetics; plectin; poly(ADP-ribose) polymerase; proteomics; targeted drug delivery

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'ovaire / Plectine / Nanoparticules / Inhibiteurs de poly(ADP-ribose) polymérases / Liposomes / Antinéoplasiques Limites: Animals / Female / Humans Langue: En Journal: Theranostics Année: 2018 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Australie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google